Merck & Co., Inc. (NYSE: MRK) announced its transformation is underway during a discussion with Chairman and CEO Rob Davis at a Morgan Stanley event. Davis highlighted positive clinical readouts and the expectation of additional regulatory filings within the year. The company projects over $70 billion in revenue from new launches and pipeline products by the mid-2030s, with particular emphasis on its Animal Health segment.
Merck is focusing on drug affordability and patient access, advocating for reforms on pharmacy benefit managers (PBMs) and the 340B drug-pricing program. Davis emphasized the need for system reforms that ensure manufacturers receive a fairer share of healthcare dollars, arguing that current practices disproportionately benefit intermediaries.
Additionally, Merck’s newly approved treatment, LIPFENDRA, aims to target 30 million U.S. patients not currently meeting lipid-lowering goals. The company anticipates broad commercial coverage by 2027 and Medicare coverage by 2028. Merck is also exploring direct-to-patient channels for select medications.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
